<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005472</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000634373</org_study_id>
    <secondary_id>UCLA-0711052</secondary_id>
    <secondary_id>SPRI-P05513</secondary_id>
    <secondary_id>PFIZER-GA6181FZ</secondary_id>
    <secondary_id>10-001406</secondary_id>
    <nct_id>NCT01005472</nct_id>
    <nct_alias>NCT00859326</nct_alias>
  </id_info>
  <brief_title>Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma</brief_title>
  <official_title>A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with&#xD;
      sunitinib malate may kill more tumor cells.&#xD;
&#xD;
      Phase II was never conducted due to toxicity in phase I.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib malate&#xD;
      when given together with temozolomide and to see how well they work in treating patients with&#xD;
      stage III or stage IV malignant melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the maximum tolerated dose of sunitinib malate when administered concurrently&#xD;
           with temozolomide in patients with stage IIIC or IV malignant melanoma. (Phase I)&#xD;
&#xD;
        -  Assess the overall safety of this regimen in these patients. (Phase I)&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen. (Phase II) Phase II&#xD;
           was never conducted due to toxicity in phase I.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen. (Phase I)&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients. (Phase II)&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of sunitinib malate followed by a phase II&#xD;
      study.&#xD;
&#xD;
      Patients receive oral sunitinib malate once daily and oral temozolomide once daily on days&#xD;
      1-42. Treatment repeats every 56 days for up to 1 year in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed up very 6 months for up to 5 years.&#xD;
&#xD;
      Phase II was never conducted due to toxicity in phase I.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2008</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">January 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of sunitinib malate when administered concurrently with temozolomide (Phase I)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate as assessed by modified RECIST criteria (phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Phase II was never conducted due to toxicity in phase I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by modified RECIST criteria (Phase I)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>sunitinib malate, temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <arm_group_label>sunitinib malate, temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>sunitinib malate, temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed Stage IIIC unresectable cutaneous or mucosal melanoma with&#xD;
             measureable disease or stage IV cutaneous, mucosal or ocular melanoma with measureable&#xD;
             disease.&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  age greater than or equal to 18 years&#xD;
&#xD;
          -  ANC ≥ 1,500/µL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  LDH ≤ 5 times ULN&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastasis is present)&#xD;
&#xD;
          -  LVEF ≥ 50% on screening ECHO&#xD;
&#xD;
          -  women of childbearing potential must have a negative urine or serum pregnancy test&#xD;
             upto 28 days prior to commencement of dosing.&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plans, laboratory tests,&#xD;
             and other study procedures&#xD;
&#xD;
          -  before study entry , written informed consent must be obtained. Written informed&#xD;
             consent must be obtained from patient prior to performing any study related&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  any following within the past 12 months:&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Severe and/or unstable angina&#xD;
&#xD;
          -  Coronary and/or peripheral artery bypass graft&#xD;
&#xD;
          -  Symptomatic congestive heart failure&#xD;
&#xD;
          -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
          -  Pulmonary embolism&#xD;
&#xD;
          -  ongoing cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0&#xD;
&#xD;
          -  prolonged QTc interval on baseline EKG&#xD;
&#xD;
          -  uncontrolled hypertension (i.e., blood pressure &gt; 150/100 mm Hg despite optimal&#xD;
             medical therapy)&#xD;
&#xD;
          -  pre-existing thyroid abnormality with thyroid function that cannot be maintained in&#xD;
             the normal range with medication&#xD;
&#xD;
          -  any known clinically uncontrolled infectious disease, including HIV positivity or&#xD;
             AIDS-related illness&#xD;
&#xD;
          -  severe acute or chronic medical or psychiatric condition or laboratory abnormality&#xD;
             that may increase the risk associated with study participation or study drug&#xD;
             administration or may interfere with the interpretation of study results, and, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for study entry&#xD;
&#xD;
          -  prior chemotherapy for melanoma, except for chemotherapy given during isolated limb&#xD;
             perfusion for stage IIIC disease&#xD;
&#xD;
          -  Prior adjuvant immunotherapy and/or immunotherapy for metastatic disease allowed&#xD;
&#xD;
          -  prior major surgery, radiotherapy, or immunotherapy within 4 weeks of starting therapy&#xD;
&#xD;
          -  treatment with potent CYP3A4 inhibitors 7 days before study dosing&#xD;
&#xD;
          -  treatment with potent CYP3A4 inducers 12 days before study dosing&#xD;
&#xD;
          -  concurrent treatment on another clinical trial (Concurrent participation on supportive&#xD;
             care trials or non-treatment trials (e.g., quality-of-life trials) allowed).&#xD;
&#xD;
          -  concurrent chemotherapy, immunotherapy, biological therapy, or investigational drugs&#xD;
&#xD;
          -  concurrent drugs with dysrhythmic potential, including any of the following:&#xD;
&#xD;
          -  Terfenadine&#xD;
&#xD;
          -  Quinidine&#xD;
&#xD;
          -  Procainamide&#xD;
&#xD;
          -  Disopyramide&#xD;
&#xD;
          -  Sotalol&#xD;
&#xD;
          -  Probucol&#xD;
&#xD;
          -  Bepridil&#xD;
&#xD;
          -  Haloperidol&#xD;
&#xD;
          -  Risperidone&#xD;
&#xD;
          -  Indapamide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartosz Chmielowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2009</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

